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Lymphoid Markers at Diagnosis and at Relapse 
By Ching-Hon Pui, Susana C. Raimondi, David R. Head, Michael J. Schell, Gaston K. Rivera, Joseph Mirro, Jr, 
William M. Crist, and Frederick G. Behm 
To define the clinical and biologic significance of childhood 
acute mixed-lineage leukemia diagnosed by stringent crite- 
ria,  we studied 25 cases  of  acute  lymphoblastic leukemia 
expressing 2  2 myeloid-associated antigens (My+  ALL),  and 
16 cases of acute myeloid leukemia expressing 22  lymphoid 
associated antigens (Ly+ AML).  These  cases  represented 
6.1 % of 410 newly diagnosed ALLs (two  treatment protocols) 
and 16.8% of 95 AMLs (two  protocols).  T-lineage-associated 
antigens  were identified in  9 of the My+  ALL cases and in 14 of 
those classified as  Ly+ AML;  all but 1 of the 19 cases that 
could  be  subclassified had  an  early thymocyte stage  of 
differentiation. The  My+ ALL  cases  had an  increased fre- 
quency  of  French-American-British (FAB)  L2  morphology 
(36%); the Ly+  AML cases were characterized  by FAB M1 or 
M2 morphology, low levels of  myeloperoxidase reactivity 
and combined populations  of myeloperoxidase-positive  large 
blasts  and small blasts generally of hand-mirror  morphology. 
LTHOUGH LEUKEMIC cells generally exhibit char-  A  acteristics of  a single lineage, they sometimes coex- 
press both lymphoid and myeloid features.’.”  This lineage 
heterogeneity has been variously explained as a reflection 
of  aberrant gene expression, malignant transformation of 
pluripotent  progenitor  cells capable of  differentiation in 
either the lymphoid or myeloid pathway, or immortalization 
of  rare  progenitor  cells  coexpressing  features  of  both 
 lineage^.'.^ Numerous terms have been used to designate 
these cases, but standard nomenclature is still lacking. Gale 
and Bassat”  suggested “hybrid acute leukemia” for cases 
showing features of both lymphoid and myeloid cells. This 
entity comprises both the relatively common biphenotypic 
leukemias, in which 2  10% of  the leukemic cells coexpress 
lymphoid  and  myeloid  features,  and  the  rare  bilineal 
leukemias, in which two distinct populations of  blast cells, 
one expressing lymphoid markers and the other myeloid 
features, coexist in the same patient. We have used the term 
acute mixed-lineage leukemia (AMLL) to describe cases in 
which the leukemic cells coexpress lymphoid- and myeloid- 
associated antigem5 
The above terminology describes only the coexpression 
of  myeloid- and lymphoid-associated antigens by leukemic 
cells; it does not reflect the heterogeneity that characterizes 
the entire spectrum of  mixed-lineage phenotypes. There is 
increasing evidence, clinical as well as biologic, for distin- 
guishing acute lymphoblastic leukemia (ALL) with myeloid- 
associated antigens from acute myeloid leukemia (AML) 
with  lymphoid-associated   antigen^.^^'^^^^-'^  Yet,  the use  of 
different diagnostic criteria and lineage-related monoclonal 
antibodies (MoAbs); the lack of  specificity for virtually ail 
known “differentiation” antigens, as well as Ig and T-cell 
receptor gene rea~~angements~,’’,~-~*;  the inclusion of  clini- 
cally diverse patient populations; and treatment with vastly 
different regimens have clouded rather than clarified this 
issue. Therefore, we studied a large cohort of children with 
vigorously diagnosed AMLL to identify morphologic, immu- 
nologic, cytogenetic, and clinical features that might define 
Karyotypic abnormalities included t(9;22)(q34;qll)  in three 
cases of My+  ALL,  11q23 translocations in two cases of My+ 
ALL,  and 14q32 translocations in  three My+  ALL and five Ly+ 
AML cases. Mixed-lineage expression lacked prognostic sig- 
nificance in either ALL or AML;  however, the findings indi- 
cate that  some  patients with Ly+ AML  may respond to 
prednisone, vincristine, and L-asparaginase after failing on 
protocols for myeloid leukemia. At relapse, two My+ ALLs 
had converted to  AML and two Ly+  AMLs to  ALL;  one case in 
each group showed complete replacement of the original 
karyotype.  Acute  mixed-lineage leukemia does  not ade- 
quately describe the heterogeneity  of the cases identified in 
this study and should be replaced  by a set of more restrictive 
terms that indicate the unique biologic features of  these 
leukemias. 
0 1991 by  The American Society of Hematology. 
unique  subtypes  within  the  broad  category  of  “mixed- 
lineage” leukemia. 
MATERIALS AND METHODS 
From  March  1984 to  April  1990, 453  consecutive 
children with  newly  diagnosed ALL and  103 with  AML  were 
admitted to St Jude Children’s Research Hospital (Memphis,  TN). 
Four hundred ten (91%) of the former group and 95 (92%) of the 
latter had  complete leukemic cell  immunophenotyping that  in- 
cluded evaluation of  lymphoid- and  myeloid-associated antigen 
expression. 
Patients with ALL were treated in Total Therapy Studies XI and 
XII,’3*34  which  featured  intensive  multiagent induction therapy 
(prednisone,  vincristine, L-asparaginase,  daunorubicin, teniposide, 
and cytarabine),  followed in the first trial33  by a consolidation  phase 
(high-dose methotrexate with leucovorin rescue). Patients in Study 
XI then received intensive continuation therapy with four pairs of 
drugs for 120 weeks: etoposide + cyclophosphamide,  mercaptopu- 
rine + methotrexate, teniposide + cytarabine, and prednisone + 
vincristine. Those in Study XII” received continuation therapy of 
120 weeks with  mercaptopurine and  methotrexate, interrupted 
Patients. 
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every  6 weeks  (up to week  55) by  pulses of  either  high-dose 
methotrexate or teniposide-cytarabine. 
Half  of  the patients with AML were enrolled on the AML-83 
protoc~l~~  which specified etoposide and cytarabine before conven- 
tional induction  therapy  with daunorubicin, cytarabine,  and thiogua- 
nine. Continuation treatment of  22 months was based on rotation 
of  four pairs of  drugs: vincristine + doxorubicin, thioguanine + 
cytarabine, etoposide  + cyclophosphamide, and  vincristine  + 
amsacrine. The remaining patients were treated according to the 
AML-87 protocol,M  in which  four pairs of  drugs-etoposide  + 
cytarabine, daunorubicin + cytarabine, etoposide + amsacrine, 
and etoposide + 5-azacytidine-were  administered over 6 to 8 
months. 
Informed  consent was  obtained  for  the  participation of  all 
patients, and the investigations  were approved by  the institution's 
review committee for clinical trials. 
Bone marrow cells were 
stained by  standard techniques, including  Wright-Giemsa,  periodic 
acid-Schiff reagent, Sudan black  B,  myeloperoxidase, naphthol 
AS-D chloroacetate esterase, and a-naphthyl butyrate esterase. 
Bone marrow cells were separated on a 
Ficoll-Metrhate  gradient  (Pharmacia, Uppsala,  Sweden; Ny- 
comed, Oslo, Norway),  and only samples containing more than 
85% blasts were assayed. Cell surface antigens were detected by  a 
standard indirect immunofluorescence assay with MoAb to HLA- 
DR, CD10, lymphoid-associated antigens (CD19,  CD20, CD22, 
CD7, CD5, and CD2), and myeloid-associated antigens (CD33, 
CD13, CD15, CDllb,  CD14, and CD36). Fluorescence activity was 
analyzed  on an EPICS C flow  cytometer equipped with  a 5-W 
Morphologic and cytochemical studies. 
Immunophenotyping. 
coherent laser (Coulter, Hialeah, FL). Isotypically matched my- 
eloma Igs  at the same protein concentrations  were used as negative 
controls in all experiments. Results were considered positive if 
220% of  the cells expressed a particular myeloid or lymphoid 
antigen. Blast cells were also tested for surface (slg) and cytoplas- 
mic (cIg) Igs (2  10% of  cells positive). Terminal deoxynucleotidyl 
transferase (TdT) activity, detected by  a standard immunofluores- 
cence assay, was  considered positive  if  215% of  cells demon- 
strated nuclear fluorescence. 
The diagnosis  of ALL or AML was based on 
morphologic and cytochemical criteria of  the French-American- 
British (FAB) Cooperative  Thus, by definition, all cases 
of  ALL had fewer than 3% myeloperoxidase-positive,  3% Sudan 
black  B-positive  (myeloid  pattern),  or  20%  butyrate  esterase- 
positive (myeloid pattern) blast cells and no Auer rods. On the 
basis of  their pattern of  reactivity to MoAb, lymphoblasts were 
classified as T (CD7+,  CDS',  CDZ'),  early pre-B (CD19+,  CD7-, 
CDY, cIg-, slg-), pre-B (cIg+),  or B   SI^+).^^ 
Given the nonspecific nature of the cell surface antigens, cases of 
ALL were considered to have mixed-lineage  expression only if  the 
leukemic cells coexpressed two or more myeloid-associated anti- 
gens. Similarly, mixed-lineage  expression in AML was based on the 
coexpression  of two  or more lymphoid-associated  antigens. For the 
purpose of this study, cases of AMLL were subdivided into myeloid 
antigen-positive (My+) ALL or lymphoid antigen-positive (Ly') 
AML. 
Chromosome analysis.  Bone marrow samples were prepared by 
the method of  Williams et a1,4 and metaphases were G-banded by 
treatment with trypsin and studied with Wright stain. Chromosome 
Diagnostic criteria. 
Table 1.  Clinical and Laboratory Features of 25 My+  ALL Cases 
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Liver/ 
Leukocyte  Platelet  Spleen  Serum  Remission 
Patient  Age  Count  Hemoglobin  Count  Size"  CNS  Mediastinal  LDH  Duration  Type of 
No.  (y)  Race  Sex  (xlOs/L)  (g/dL)  (x  10g/L)  (cm)  Leukemia  Mass  (IU/L)  (mo)  Failure 
43  +  -  299  12  H 
-  010 
010 
2/0 
616  + 
016 
1  IO 
110 
516 
413 
719  + 
614 
40  + 
1118  - 
010 
010 
511 
010 
716 
412  + 
010 
511 2  - 
31 1 
010 
- 
- 
- 
- 
1118  + 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
+  358 
-  549 
+  428 
+  694 
-  165 
+  154 
-  6,084 
-  1,035 
-  327 
-  314 
-  320 
49 1 
-  213 
-  999 
-  520 
-  324 
-  598 
-  744 
-  935 
61  5 
-  304 
-  878 
-  239 
-  186 
- 
- 
22+ 
13  H 
25+ 
9  H 
40+ 
25+ 
4+ 
14+ 
48+ 
14+ 
14+ 
52 + 
14+ 
32+ 
38  AML 
16+ 
11+ 
9+ 
2  AML 
46+ 
32 + 
39  H 
71+ 
7  H 
Abbreviations: W,  white;  E, black;  F,  female;  M,  male; LDH,  lactic dehydrogenase; H,  hematologic relapse; AML, acute myeloid leukemia; 
*Edge palpable below the costal margin. 
+, present; -,absent. 
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Fig 1.  Comparison of event-free survival [EFS) in My'versus other 
ALL  cases.  The  difference  between the  curves  is  not  significant 
(P = .45 by log-rank test). Tick marks denote patients still at risk of 
failure. 
abnormalities  were classified according to the International  System 
for Human Cytogenetic Nomenclature!' 
Differences in  the  distribution of  clinical 
and biologic features among subgroups of patients were analyzed 
by  Pearson's  chi-square test  for  categorical variables  or  the 
Kruskal-Wallis test for continuous variables. Life tables for event- 
free survival were constructed  by the method of Kaplan and Meier, 
with differences compared by  the log-rank test. Early death or 
failure to enter remission was considered an event at zero time. 
Patients with AML who underwent bone marrow transplantation 
were censored at the time of the procedure. 
Stuiistical  analysis. 
RESULTS 
Myeloid  antigen expression was  de- 
tected  in  25  (6.1%) of  the 410  cases of  childhood ALL 
(Table 1).  Except for higher initial platelet counts (median, 
142 v  55 x lo9&  P  = .001)  and  increased  frequency of 
Clinical findings. 
initial central nervous system (CNS) leukemia (24% v 8%, 
P  = .02),  the  25  My'  and  385  My-  cases  had  similar 
presenting features, including sex ratio, race distribution, 
frequency of mediastinal mass, liver or spleen size, hemoglo- 
bin level, leukocyte count, and serum lactic dehydrogenase 
level (data not shown). All patients with My+ ALL achieved 
complete remission, with seven having a subsequent ad- 
verse  event  (hematologic relapse  in  five  and  secondary 
AML in two). Event-free survival in these 25 cases did not 
differ significantly from that of  the other 385 ALL cases 
(P = .45; Fig 1). 
Sixteen (16.8%) of  the 95 cases of AML were classified as 
Ly'  AML (Table 2). Overall, the presenting features of the 
16 patients with Ly'  AML were similar to those of the other 
79 AML patients (data not shown). AML-directed therapy 
failed to induce complete remissions in four patients (nos. 
28,  29,  37,  and  39),  two  of  whom  (nos.  29  and  39) 
subsequently  entered remission during treatment with pred- 
nisone, vincristine, and Gasparaginase. Event-free survival 
did not  differ between this group of  patients  and other 
Ah4L patients (Fig 2, P  = .81). Among the four Ly+ AML 
patients remaining in continuous complete remission, one 
(no. 29) had been in the group treated with ALL-directed 
induction therapy, and another (no. 35) had received an 
allogeneic bone marrow transplant with cells from his twin 
brother. 
In virtually all patients,  there was 
wide overlap in the percentage of leukemic cells expressing 
lymphoid or myeloid antigens, indicating that some blasts in 
each  child were  coexpressing markers  of  both  lineages 
(Tables 3 and 4). 
The My'  ALL cases could be  subclassified into three 
groups according to the pattern of lymphoid antigen expres- 
sion: T (cases 1  through 7), early pre-B (cases 8 through 20), 
and pre-B (cases 21 through 25) (Table 3), a distribution 
Immunophenotype. 
Table 2.  Clinical and Laboratory  Features of 16 Ly' AML Cases 
Liver/  Myeloper-  Sudan 
Leukocyte  Platelet  Spleen  oxidase  Black B 
Patient  Age  Count  Hemoglobin  Count  Size  Positive  Positive  Auer  Duration  Type of 
No.  (y)  Race  Sex  (xlOs/L)  (g/dL)  (x  10s/L)  Icm)*  (%)  (Oh)  Rods  (mol  Failure 
Remission 
26  3WF  214  5.8  98  612  6  15  +  8  H 
27  11  W  F  88.3  6.3  63  010  8  20  +  13  H 
28  11  W  M  1  .o  6.9  18  010  7  5  +  0  IF 
29  12  W  F  19.6  9.4  103  010  6  10 
30t  2WF  10.8  10.2  133  415  29  60  43  H 
31  12  W  M  11.4  8.2  195  010  84  50  +  19  H 
32  14  W  F  10.6  14  296  311  14  20  +  12  ALL 
33  18  W  F  103  9.6  48  010  21  40  7  H 
34t  18  W  M  22  10.9  125  110  12  40  +  6  H 
35  1WM  59.2  9  43  319  0  0 
36  2B  F  472  9.6  12  715  7  7  37  H 
37  1%  w  M  22.4  8.6  165  010  3  10  - 
38  9WF  9.6  9.6  450  014  6  8  32  ALL 
39  14  W  F  117  10  61  112  8  20  8  H 
40  18  W  M  36  7.7  12  010  11  50  27+ 
41t  17  W  M  14.9  4.8  40  010  80  60  i  38 + 
72+  - 
- 
- 
76+  - 
- 
0  IF 
- 
- 
- 
Abbreviations:  W, white; B,  black; F,  female; M, male; H, hematologic  relapse; IF, induction failure; +, present; -,  absent. 
*Edge palpable below the costal margin. 
tHad initial CNS leukemia. 
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Fig 2.  Comparison of event-free survival (EFS) in Ly+  versus other 
AML  cases.  The  difference  between the curves is  nor significant 
[P = .81 by log-rank test). Tick marks denote patients still at risk of 
failure. 
not significantly different from that of other ALL cases. In 
all T-cell cases,  antigen  expression corresponded  to the 
early thymocyte stage of  maturation (CD7+,  CD5',  CD2', 
CD1-,  CD3-,  CD4-,  and  CD8-)";  CD33,  CD13,  and 
CDllb were  the  most  commonly  expressed  myeloid- 
associated antigens. Three of the T-cell cases studied (nos. 
3,  4, and 7) also expressed CD56 and CD57, markers of 
natural killer cells. There were no distinguishing patterns of 
myeloid antigen expression among the early pre-B or pre-B 
cases. Two of  the early pre-B cases expressed T-lineage 
antigens (CD2 and CD4 in case 14, and CD4 in case 15); 
conversely, two of  the T-cell cases (nos. 5 and 7) expressed 
CD21, a B-lineage antigen. Of  the 16 My+  ALL cases tested 
for platelet-associated antigen CD36, CD41, and/or CD61, 
blast cells from a single case (no. 23) expressed CD41 but 
otherwise lacked features characteristic of  megakaryoblas- 
tic leukemia. 
Of  the  16  Ly+ AML cases,  12 (nos.  26  through  37) 
expressed T-cell antigens, 2 (nos. 38 and 39) B-precursor 
cell  antigens,  and  2  (nos.  40  and  41)  both  T-cell  and 
B-precursor cell antigens (Table 4). Among the Ly+ AML 
cases with T-cell antigen expression, all but two of  those 
tested  (nos.  28  and  40)  were  CD7'  and  CD2'.  None 
expressed CD1 and CD8; only case 34 was CD4+;  and case 
36  was CD3'  plus CD4'.  Thus, of  the cases with T-cell 
antigens, only case 36  had a pattern of  antigen expression 
Table 3.  lmmunophenotype of Leukemic Cells in 25 My' ALL Cases 
&Lineage  T-Lineage  Myeloid-Associated Antigens 
Patient  Time of 
NO.  Study'  TdT  HLA-DR  CDlO  CD19  CD20  CD22  Clg  CD7  CD5  CD2  CD33  CD13  CD15  CDllb  CD14  CD36 
-  -  -  -  -  75  -  58  -  86  77  61  61  -  1  D  -  27 
-  95  93  -  88  69  -  87  -  R  -  70 
-  93  -  -  97  98  -  92  -  2  D  38  - 
3  D-  -  -86--91 -  -  85  - 
-  -  -  -  -  91  -  90  83  88  -  65  - 
-  -  -  -  -  94  93  38  -  57  -  42  - 
-  -  -  -  - 
-  -  -  -  - 
-  -  -  -  - 
-  -  -  -  -  R  -  ND  75  -  -  83  -  -  57  -  - 
4  D  -  91 
5*  D  67  - 
- 
- 
-  -  -  -  R  81  20  -  -  -  ND  70  79  -  -  63  - 
6  D  -  50  43  -  -  ND  -  62  62  66  24  -  -64-ND 
-  -  -  -  95  92  93  43  60  -  84  -  7'  D  -  68  - 
8  D  81  86  -  92  -  84  -  -  -  -  -  -5946- - 
- 
9  D  91  92  92  94  60  93  -  -  -  -  -  81  57  80  - 
-  30  65  -  10  D  97  95  93  94  41  ND  -  ND  -  - 
-  52  77  -  11  D  96  96  97  97  -  97  -  -  -  - 
-  -  -  51  63  -  12  D  91  95  93  92  52  90  -  -  -  - 
13  D  100  90  93  95  90  ND  -  ND  -  -  ND  -  -  50  ND  46 
R  100  65  71  57  37  ND  -  ND  -  -  43  ND  ND  ND  ND  ND 
14t  D  -  80  20  90  21  ND  -  ND  -  40  ND  30  -  70  ND  53 
15t  D  88  93  92  91  90  93  -  -  -  -  68  74  -  78  69  76 
-  60  69 
17$  D  -  95  88  95  47  ND  -  -  -  -  94  88  -  ND  -  ND 
65  80  -  -  -  -  18  D  61  70  72  72  -  72  -  -  -  - 
19  D  91  62  81  91  25  78  -  -  - 
20  D  92  87  91  90  28  81  -  -  -  -  -  73  81  - 
21  D  -  94  -  88  -  ND25-  -  -  33  -  24  28  64  - 
- 
-  - 
-  - 
16  D  75  93  91  92  -  89  -  -  -  -  93  79  - 
-  91  81  -  -  -  - 
-  - 
-  -  -  ND15-  -  -  22  -  54  -  -  -  R  -  60 
22  D  79  92  90  87  63  ND  92  ND  -  -  22  -  ND  ND  24  ND 
23  D  99  82  86  87  24  43  92  -  -  -  34  39  40  -  50  34 
24  D  51  97  97  95  -  97  98  -  -  -  98  98  98  -  -  - 
R  45  96  95  95  44  89  96  -  93  -  92  54  93  75  -  - 
25  D  86  96  98  ND  -  ND  29  ND  -  -  ND  43  93  -  ND  - 
Abbreviations: clg, cytoplasmic immunoglobulin; -,  negative result (<20% positivity);  ND, not done; D, diagnosis; R, relapse. 
*Expressed CD21 (69% and 52%. respectively). 
tExpressed CD4 (20% and 79%. respectively). 
*Not tested at lineage switch. 
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Table 4.  lmmunophenotypic Pattern of Leukemic Cells in 16 Ly+  AML Cases 
8-Lineage  T-Lineage  Myeloid-Associated  Antigens 
Patient  Time of 
No.  Study  TdT  HLA-DR  CDlO  CD19  CD20  CD22  Clg  CD7  CD5  CD2  CD33  CD13  CD15  CDllb  CD14  CD36 
-  -  -  -  -  85  -  98  -  55  -  -  -  - 
-  -  -  -  -  86  -  91  -  -48- 
-  -  -  ND  -  70  -  95  -  38  ND  ND  -  ND 
-  -  -  -  -  54  -  -  56  63  -  -  61  73 
-  -  -  -  -  90  58  -  33  65  -  -  28  D  56  - 
29  D  -  52  -  -  -  ND  -  78  -  89  ND  64  21  ND  ND  - 
-  -  -  ND  -  84  -  67  86  46  -  86  53  -  61  - 
26  D  95  93 
R  80  93 
27  D  90  87 
R  88  53 
-  - 
-  - 
30  D 
-  -  -  41  -  76  - 
31  D  41  82  -  -  -  -  91  -  89  -  84  63  - 
-  -  -  -  -  86  -  90  -  84  60  - 
----  R  -  92  -  82  - 
R  61  83 
-  -  - 
-  - 
32  D  53  68  31  -  -  ND  -  84  34  76  ND  38  -  ND  ND  - 
R  ND  45  37  -  -  ND  -  ND  70  72  ND  ND  ND  60  ND  50 
-  -  -  33  D  33  90  -  -  -  -  85  -  86  -  94  22  - 
R  53  90  -  -  -  ND  87  -  86  -  85  -  -  -  -  - 
-  97  -  -  -  -  -  44  -  36  95  72  31  33  70  28 
35  D  88  -  -  -  -  ND  -  ND  66  51  ND  44  -  ND  ND  85 
-  -  ND  -  97  96  96  -  -  ND  -  -  ND 
-  -  -  -  ----  99  77  70  80  56  61 
37  D  52  75  -  -  -  ND  -  89  -  76  ND  54  20  34  ND  20 
38  D  85  77  -84-87----  -  -  -  71  36  - 
R  ND  96  72  92  -  88  -  -  -  -  93  80  - 
39  D  95  93  21  75  -  96  41  -  -  -  69  32  55  20  33  37 
34  D* 
36  D*  -  -  - 
R  -  35 
-  -  - 
-  -  -  -  -  -  Rt(a)  71  77  20  59  -  69  31  -  -  - 
-  -  -  -  -  ----  -  76  -  73  61  -  (b)  - 
-  --  -  22  58  54  -  -  -  -  40  D  -  65  -  30  - 
41  D  -  95  -  59  59  ND  -  67  -  69  76  90  -  ND  70  - 
Abbreviations: clg, cytoplasmic immunoglobulin; -, negative result (<20% positivity); ND, not done; D, diagnosis; R,  relapse. 
*Additional T-associated antigen expression included CD4 (67%) in case 34 and CD3 (96%)  plus CD4 (66%) in case 36. 
tPressnce of two populations of blast cells at relapse: small cells of B-lineage (a) and large cells of myeloid-lineage (b). 
corresponding to that of the late thymocyte phenotype; all 
others had an early thymocyte phenotype. Ten of  the Ly+ 
AML cases were positive for TdT and three for CD10. 
Mophology.  FAB L2 morphology characterized 36% of 
the My'  ALL cases (Table 5), compared with only 19% of 
the  other  ALL  cases  (P  = .03).  Unusual  leukemic  cell 
morphologic features in the My+ cases included the pres- 
ence of  azurophilic granules in the cytoplasm of  greater 
than 5% cells in two cases (nos. 16 and 21), hand-mirror 
morphology in greater than 40% blasts in two  (nos. 6 and 
9), the coexistence of separate cell populations of large and 
small blasts in two (nos. 14 and 21), and phagocytosis in one 
(no. 18). 
FAB  designations for the 16 Ly+  AML cases were M1 in 
eight, M2 in five, M4 in two, and M5 in one (Table 6). The 
proportion with FAB M1 or M2 morphology was  much 
higher in this group of patients than in other AML patients 
(81% v 42%, P  = .005). Myeloperoxidase activity was dem- 
onstrated in all Ly+ cases but the one with M5 leukemia; 11 
of  the cases were characterized  by  3% to 14% positivity 
(Table 2). Sudan black B reactivity generally paralleled that 
of myeloperoxidase. Coexisting populations  of  large  and 
small blasts were found in 11 Ly+  cases (nos. 26 through 29, 
31 through 33,36,37,39, and 40). In each of these, the large 
blasts  were  myeloperoxidase-positive, and  in  seven  the 
small blasts had hand-mirror morphology (excluding cases 
26,36,39, and 40) (Fig 3). 
Cytogenetics.  Leukemic  cell  chromosomal  abnormali- 
ties were apparent in 19 (76%) of the 25 cases of My+  ALL 
(Table 5).  Modal chromosome numbers were 45 (n = l),  46 
(n = 16), 47 to 50 (n = 4), and greater than 50 (n = 4). Ten 
cases had chromosomal translocations and four deletions. 
Well-recognized  recurring  abnormalities  included  t(9; 
22)(q34;qll)  in  three  cases,  and  t(4;11)(q21;q23),  t(9; 
11)(q21;q23), and t(1;19)(q23;p13) in one case each. The 
chromosomal regions most often affected by the rearrange- 
ments were 9q34 (n = 3), 14q32 (n = 3), and 22qll (n = 3); 
two cases had involvement of llq23. 
Nine cases of  Ly+ AML (56%) had translocations, five 
involving 14q32, and four had deletions. The modal chromo- 
some  numbers  of  the  stem  lines  were  46  (n = 13), 47 
(n = 2), and 51 (n = 1). The prevalence of  chromosomal 
abnormalities overall was 69% (11 of 16 cases). 
Overall, 14q32  rearrangements were found in eight cases. 
Interestingly, the same translocation, t(7;14)(p15;q32) was 
detected  in one case each of  My+ ALL (no. 1) and Ly' 
AML (no. 32). 
Five cases of My+ ALL (nos. 1, 3, 5, 
13, and 24) and four of Ly+ AML (nos. 26, 27, 31, and 33) 
had minor or no changes in karyotype and phenotype at 
relapse (Tables 3 through 6). Two patients (nos. 17 and 21) 
with My+ ALL subsequently developed AML; sequential 
cytogenetic studies showed an entirely different karyotype 
at lineage switch in case 17 and clonal evolution in case 21 
(Table 5). Conversely, two patients with Ly+ AML (nos. 32 
and 38) had a lineage switch to ALL with loss of myeloper- 
Studies at relapse. 
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Table 5.  Leukemic Cell Kanotwe at Diagnosis and at RelaDse in 25 Mv'  ALL Cases 
~~  ~ 
Patient  Time of  Lymphoid 
No.  Study  FA6  Marker  Kawotype 
45,XX,dic(l2;  18)(pll  ;pl  1  ),t(l;2)(p22;p14),t(7;  14Hpl  5;q32)  1  D 
R 
2  D 
3  D 
R 
4  D 
5  D 
R 
6  D 
7  D 
8  D 
9  D 
10  D 
11  D 
12  D 
13  D 
R 
14  D 
15  D 
16  D 
17  D 
R 
18  D 
19  D 
20  D 
21  D 
R 
22  D 
23  D 
24  D 
R 
25  D 
L2 
L2 
L1 
L2 
L2 
L2 
L2 
L2 
L1 
L1 
L2 
L2 
L1 
L1 
L1 
L1 
L2 
L1 
L2 
L1 
L1 
M4 
L1 
L2 
L1 
L2 
M5 
L1 
L1 
L1 
L1 
L1 
~ 
T 
T 
T 
T 
T 
T 
T 
T 
T 
T 
Early pre-B 
Early pre-B 
Early pre-B 
Early pre-B 
Early pre-B 
Early pre-B 
Early pre-B 
Early pre-B + T 
Early pre-B + T 
Early pre-B 
Early pre-B 
Not  tested 
Early pre-B 
Early pre-B 
Early pre-B 
Pre-B 
Pre-B 
Pre-B 
Pre-B 
Pre-B 
Pre-B + T 
Pre-B 
45,XX,dic(l2;  18)(pll  ;pl 1  ),t(l;2)(p22;p14).t(7;  14)(pl5;q32) 
46,XY,inv(7)(pl3q36),1 qh  -/46,XY,lqh-(constitutional) 
49,XX,+?22,-3.+der(3)t(l;3)(ql2;q29),+marl  ,+mar2 
49,XX,+?22,-3,+der(3)t(1;3)(ql2;q29),+~arl,+mar2 
46,XX,t(4;  1  1  )(q21;pl4-p15) 
52,XY,+8,+21,+?22,de1(15)(ql5q22),+  marl, 
52,XY,+8,+21,de1(15)(q15q22),+mar  l,+mar2,+mar3,+mar4 
46,XY 
46,XX,t(4;1  l)(q21;q23) 
5O,XX,+X,+X,+1O,-2O,i(8q),i(21q),+i(21q),+f 
57,XX,+X,  +  1, +4, +6, +  1  1  ,+ 14, +  17,+  18. +21,+  2  1  ,t(l ;  19)(q23; 
pl3). +  mar/57,XX,+X,  +4,+6,+  1  1, +  14,+ 17, +  18, +  2  1, +  21, 
+der(19)t(1;19)(q23;~13),+mar 
+mar2,+mar3/47,XY,+8 
47,XY,+4,t(l2;  14)(ql3;q32) 
56,XY,+X,+4,+6,+  10,+14,+  17,+18,+19,+21,+21 
55,XX,+X,+4,+6,+10,+14,+17,+18,+21,+22,dup(1)(q21  -+  q42)/ 
46,XY,del(3)(p23),del(7)(pl3pl5),inv( 12)(pll  pl3) 
46,XY,del(3)(p23),del(4)(q?l  lq2l),del(7)(pl3pl5),inv(l2) 
46,XY 
46,XY,t(9;22)(q34;q  11  )/46,XY,t(9;22;?)(q34;qll  pl  l;?) 
46,XY 
46,XX,deI(l l)(p13) 
46,XX,t(3;8)(p21 ;p21 ),t(9; 1  1  )(p22;q23),t(l2; 17)(q22;q25) 
46,XY 
46,X.-X,+  mar 
46,xx 
46,XX,t(9;  1  l)(p21;q23) 
46,XX,t(9;1  l)(p21;q23)/47,XX,+3,t(9;11)(  p21;q23) 
47,XY.-  1  ,+der( l)t(l  ;?)(p36;?),t(9;22)(q34;ql  l),der(22)t(9; 
22)(q34;ql l),+mar 
46,XY,t(8;  14)(ql  l;q32).t(9;22)(q34;ql l),-15,  +der(l5)t(15;?) 
(p11;?)/46,XY,t(8; 14)(qll  ;q23),t(9;22)(q34;qll  ),i(l7q)/addi- 
tional related lines 
55 ,XX,+X,+4,+6,+10,+14,+17,+18,+21,+22 
(pl  lpl  3)/46,XY,del(3)(p23),de1(7)(pl3pl5),inv(l2)(pll  p13) 
46,XY 
46,XY 
46,XX,de1(9)(~21) 
Abbreviations: D,  diagnosis; R,  relapse. 
oxidase and Sudan black B positivity. Case 32 retained the 
same  immunophenotype  and  karyotype,  while  case  38 
gained CDlO at lineage switch and had an entirely different 
karyotype,  including  a  t( 12;13)(p13;q14),  a  nonrandom 
rearrangement recently identified in association with ALL43 
(Tables 4  and 6). Two other Ly'  AML cases (nos. 30 and 
36) had major changes in immunophenotype. Case 30 lost 
T-cell antigens, gained other lymphoid antigens compatible 
with an early pre-B phenotype, and continued to express 
myeloid antigens. Case 36 lost all lymphoid antigens, gained 
at least four myeloid antigens, and converted from M1 to 
M2 morphology. In both cases, the original karyotype had 
been replaced by an entirely different abnormal karyotype; 
at relapse, case 30 had a t(8;21)(q22;q22), a well-recognized 
translocation in patients with AML. Finally, a case of  Ly' 
AML  (no.  39)  had  marked  clonal  evolution  with  two 
separate cell populations at relapse, one consisting of  small 
blasts with  a pre-B  immunophenotype  and  the  other of 
large blasts  with  myeloid  markers  and  myeloperoxidase 
expression (Table 4). 
DISCUSSION 
Myeloid antigen expression in ALL appears more com- 
mon in adults than in children. In six combined series of 
adult ALL cases, 113 (33.3%) of 339 patients had lympho- 
blasts with myeloid  feature^,'^^'^"'^^^^^^^^ in contrast to find- 
ings in childhood ALL, where the reported  frequency of 
myeloid antigen expression ranges from 3.5%  to 22%  of 
cases.6,13.18,20,27  This wide variation undoubtedly reflects the 
use of different panels of cell lineage markers, immunophe- 
notyping techniques,  and  diagnostic criteria.  The preva- 
lence of  lymphoid antigen expression in AML is even less 
certain. Current estimates, some based on studies combin- 
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Table 6.  Leukemia Cell Karyotypa  at  Dlagnosis and at Relapse in 16 Ly+  AML Cases 
Lymphoid- 
Associated 
Patient  Time of  Antigen 
No.  Study  FAB  Expression  Kwotype 
26  D  M1  T  46,XX,de1(13)(qll q14),-8,+der(8)t(8;?)(q2?2;?) 
R  M1  T  46,XX,de1(13)(q  1  1  ql4),inv( 16)(pl3q22),  -8,+der(8) 
t(8;?)(q2?2;7) 
27  D  M1  T  46,XX 
R  M1  T  46,XX 
28  D  M1  T  46,XY 
29  D*  M1  T  46,XX,t(6;  14)(q23-q25;q32) 
30  D  M2  T  46,XX,t(2;  14)(q24-q31 ;q32),t( 17; 19)(~13;q13)/ 
46,XX,del(  16)(q22),t( 2;  14)(q24-q3 1  ,q32),t(l7;  19)(pl3;  ql3) 
R  M2  Early pre-B  46,XX,t(8;21  )(q22;q22) 
31  D  M2  T  46,XY 
R  M2  T  46,XY 
32  D*  M2  T  46,XX,t(7;14)(pl5;q32) 
R  L1  T  46,XX,t(7;  14)(pl5;q32) 
33  D  M2  T  46,XX 
R  M2  T  46,XX 
34  D  M4  T  47,XY.  +  8 
35  D*  M5  T  47,XY,-14,+2l,i(l7q),+der(14)t(l;l4)(q23;q32) 
36  D  M1  T  46.XX 
R  M2  No  46,XX,-6,+der(6)t(6;?)tp24;?) 
37  D*  M4  T  46,XY.-  14,+der(14)t(14;?)(q32;7),t(7; 12)(q35;q22),del(7)(q22) 
38  D  M1  Early pre-B  46,X.-X,+8,-  16,+der(l6)t(l; 16)(q21;q13) 
R  L1  Early pre-B  46,XX,  -3,  +der(3)t(3;?)(p25;?),t(4;  12)(q22;q 13J,t(l2; 13) 
(pl3;q14)/92,XXXX,2inv(2)(p23q31),2de1(6)(p21),2t(5;  14) 
(q32;ql1),2t(l2;13)(pl3;ql4) 
t(4; 12)(ql2;p13),+mar(77)/47,XX,same,+  15 
+ der(20)t(10;~)(p13;7),+mar(?7),+marl,+mar2 
39  D  M1  Pre-B  46,XX,-7,inv(3)(p25q21  ),deJ(61(q13q21  ),de1(10)(q24), 
R  M1  Pre-B  46,XX,  -5,-  7,-  9,inv(3)(p25q2 1  ),del(6)(q  13q2  1  ),del( 1  O)(q24), -20, 
40  D  M1  Early pre-B + T  46,XY,t(7;21;8)(q?32;q22;q22) 
41  D  M2  Early pre-B + T  51,XY,+Y,+4,+6,+13,+22 
Abbreviations: D,  diagnosis;  R,  relapse. 
'Karyotype  at diagnosis previously reported in a manuscript regarding acute mixed-lineage 
ing both pediatric and adult patients, range from 10.6% to 
28.4%  .5,13,15J6,19,23 In studies requiring expression of  two  or 
more markers of  either the myeloid or lymphoid lineage, 
the diagnosis  of AMLL could be made in 6 (8%)  of 76 and 7 
(18%) of  40  cases of  adult  ALL,'2317  18  (7.6%) of  236 
pediatric ALL," 4 (4%) of 89 combined cases of pediatric 
and adult ALL,'* and 5 (3%) of  159 adult AML cases.z In 
the  present  series,  using  a  panel  of  12  lineage-related 
MoAbs and stringent diagnostic criteria, we identified My+ 
ALL in 6.1% of children and Ly'  AML in 16.8%. 
Our  cases  of  AMLL  often  expressed  one  or  more 
T-lineage-related antigens (nine of the 25 My'  ALL cases 
and 14 of the 16 Ly+  AML cases). Remarkably, of the cases 
that  could  be  subclassified  according to  the  Reinherz 
schema of T-cell differentiation," all but one had an early 
thymocyte phenotype.  Kantarjian  et alz  found  a  higher 
prevalence  of ultrastructural myeloperoxidase-positive  blasts 
in early-thymocyte T-cell  ALL than in other immunopheno- 
types of  the disease. T-cell ALL  or lymphoblastic lym- 
phoma with an early thymocyte phenotype has also been 
shown to have the potential for multilineage differentiation 
in vivo or in  Together, these findings suggest that 
progenitor  cells with  the capacity to  differentiate  along 
either the myeloid or T-lymphoid cell pathway were trans- 
formed in these cases. Rarely, acute leukemias might arise 
from a tnultipotential hematopoietic progenitor, as demon- 
strated  in  this  (cases  14,  15,  40,  and  41)  and  other 
studie~''~'~~'~  by cases with blast cells coexpressing myeloid, 
T-lineage, and B-lineage antigens. It is also possible that 
the antigens expressed may not be lineage specific, or may 
be  different at the molecular level from  their  apparent 
counterparts on normal cells. In this regard,  CD7 is not 
considered to be a T-lineage antigen by some investigators 
because of its broad spectrum of  rea~tivity.~,"  Even after 
excluding CD7 as a lymphoid marker, ail Lyf AML cases 
except no. 29 in this study at least expressed one lymphoid 
marker plus TdT or CDlO. 
An increased frequency of  L2 morphology, azurophilic 
cytoplasmic granules, acid a-naphthyl acetate esterase pos- 
itivity, and unusual morphology (monocytoid features and 
cytoplasmic buds) has been observed for blast cells of My+ 
ALL cases in  adult^.'^^^' Except for the increased proportion 
of  cases with L2 blasts (36%), the prevalence of  unusual 
morphology  in  My'  ALL  in  this  study  did  not  differ 
appreciably from findings in the My- ALL cases. Our recent 
review of  consecutive childhood ALL cases disclosed L2 
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myeloid antigens had no effect on remission induction or 
event-free  survival for  the  267  children who  had  been 
treated with the same regimen of combination chemother- 
apy."  When  reanalyzed with  the  diagnostic criteria  of 
Wiersma et al, our data again showed a lack of prognostic 
significance for myeloid  antigen expression (not shown). 
Similarly, in the current study, myeloid antigen expression 
was  not  a  factor  in the outcome of  therapy. Thus,  the 
prognostic importance of  myeloid antigen expression, like 
most other clinical and laboratory features, is treatment- 
dependent  and  can  be  abolished  with  highly  effective 
therapy. 
Treatment for Ly+ AML cases was clearly inadequate. 
With use of AML-directed therapy, these patients fared at 
least  as poorly  as those with  typical AML (Fig 2).  We 
recommend additional ALL-directed therapy in such cases, 
for the following reasons. First, two patients who failed to 
respond initially to induction therapy for AML, and three 
(cases 26,31, and 39) with relapsed Ly+  AML, subsequently 
attained a complete remission after treatment with pred- 
nisone, vincristine, and L-asparaginase. Second, some of 
these patients apparently had a subpopulation of leukemic 
lymphoblasts at presentation. Third, two  patients had ALL 
at relapse. 
Sequential phenotypic and karyotypic studies provided 
valuable insight into the pathogenesis of treatment failure. 
Although most cases showed only minor phenotypic and 
karyotypic changes, others had a lineage switch from ALL 
to AML (n = 2) or the reverse (n = 2). Two of  the four 
cases with lineage switch retained the same clonal karyo- 
typic abnormalities. In both, chemotherapy may have sup- 
pressed  the subclone representing  the primary  lineage, 
allowing the subclone of the opposite lineage to expand. It 
is also possible that chemotherapy modified the differentia- 
tion program of  the leukemic clone, inducing a  shift in 
phenotypic expression. In the remaining two patients with 
lineage switch (nos. 17 and 38), and in two others (cases 30 
and 36) with major changes in phenotypic expression, the 
original karyotype was  completely replaced  at  relapse. 
While this karyotypic change suggests the induction of a 
second neoplasm, the apparently independent clonal na- 
ture of the leukemic cell populations seen at relapse needs 
to be confirmed by studies with X-chromosome-inactivation 
 marker^.'^-^^  The  extent  to  which  AMLL  accounts  for 
secondary AML in patients with ALL56J8  is uncertain. In 
this regard, many of  the secondary AML cases we have 
observed did not have mixed-lineage expression at diagno- 
sis (C.-H.P.,  unpublished observation, January 1991). 
We conclude that acute mixed-lineage leukemia repre- 
sents a diverse group of disorders that should be individu- 
ally recognized and studied. Our findings do not indicate 
prognostic significance  for ALL with myeloid antigen expres- 
sion, but suggest the need for careful diagnosis of lymphoid 
antigen-positive AML, which may benefit from alternative 
therapy. 
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